Cardiovascular effects of tadalafil
To determine the effects of tadalafil on the cardiovascular system, safety assessments were performed on a database of >4000 subjects who received tadalafil in >60 clinical pharmacology, phase 2, phase 3, and open-label studies. In healthy subjects, tadalafil resulted in small changes in blood pressure, which are not believed to be clinically relevant. Daily administration of tadalafil 20 mg for 26 weeks in healthy male subjects or patients with mild erectile dysfunction resulted in blood pressure changes similar to those observed after placebo administration. In patients with coronary artery disease (CAD), tadalafil administration before nitrate administration resulted in small decreases in blood pressure. The resulting mean maximal change in standing systolic blood pressure (SBP) after coadministration of sublingual nitroglycerin in patients with chronic stable angina was -36 mm Hg for tadalafil 5 mg, -31 mm Hg for tadalafil 10 mg, and -28 mm Hg for placebo. In addition, a larger number of men had a standing SBP or=55 years of age) with no overt evidence of CAD, the resulting mean maximal change in standing SBP after coadministration of sublingual nitroglycerin was -25 mm Hg for tadalafil 10 mg, -29 mm Hg for sildenafil 50 mg, and -25 mm Hg for placebo. Cardiac mortality rates in tadalafil studies are consistent with the expected rate in this male population. Across all studies, the incidence rate of myocardial infarction was low in tadalafil-treated patients (0.43 per 100 patient-years) compared with patients who received placebo (0.6 per 100 patient-years), and the incidence rate was comparable to that observed in the age-standardized male population (0.60 per 100 patient-years). The incidence rate of presumed thrombotic strokes in tadalafil studies (0.27 per 100 patient-years) is comparable to the expected rate in this patient population. The data presented herein suggest that tadalafil can be safely used by healthy subjects and by patients with cardiovascular diseases. As with sildenafil, the use of tadalafil is contraindicated in patients receiving nitrate therapy because of the potential for significant hypotensive effects.
Similar articles
Kloner RA, Mitchell M, Emmick JT. Kloner RA, et al. Am J Cardiol. 2003 Nov 6;92(9A):47M-57M. doi: 10.1016/s0002-9149(03)00075-4. Am J Cardiol. 2003. PMID: 14609623 Review.
Kloner RA, Brindis RG, Cheitlin MD, Kuritzky L, Miller TA, Padma-Nathan H, Rosen RC. Kloner RA, et al. Am J Cardiol. 2003 Nov 6;92(9A):58M-65M. doi: 10.1016/s0002-9149(03)00826-9. Am J Cardiol. 2003. PMID: 14609624 No abstract available.
Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Webb DJ, et al. J Am Coll Cardiol. 2000 Jul;36(1):25-31. doi: 10.1016/s0735-1097(00)00705-1. J Am Coll Cardiol. 2000. PMID: 10898408 Clinical Trial.
Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR, Pereira A. Kloner RA, et al. J Urol. 2004 Nov;172(5 Pt 1):1935-40. doi: 10.1097/01.ju.0000142687.75577.e4. J Urol. 2004. PMID: 15540759 Clinical Trial.
Kloner RA. Kloner RA. Am J Cardiol. 2005 Dec 26;96(12B):42M-46M. doi: 10.1016/j.amjcard.2005.07.011. Epub 2005 Dec 5. Am J Cardiol. 2005. PMID: 16387566 Review.
Cited by
Mukohda M, Fang S, Wu J, Agbor LN, Nair AR, Ibeawuchi SC, Hu C, Liu X, Lu KT, Guo DF, Davis DR, Keen HL, Quelle FW, Sigmund CD. Mukohda M, et al. J Clin Invest. 2019 Mar 21;129(6):2318-2332. doi: 10.1172/JCI123462. J Clin Invest. 2019. PMID: 30896450 Free PMC article.
Lange RA, Levine GN. Lange RA, et al. Curr Cardiol Rep. 2014 Feb;16(2):445. doi: 10.1007/s11886-013-0445-4. Curr Cardiol Rep. 2014. PMID: 24408673 Review.
Curran MP. Curran MP. Drugs Aging. 2012 Sep;29(9):771-81. doi: 10.1007/s40266-012-0010-7. Drugs Aging. 2012. PMID: 23018613 Review.
Manolis A, Doumas M. Manolis A, et al. Curr Hypertens Rep. 2012 Aug;14(4):285-92. doi: 10.1007/s11906-012-0276-5. Curr Hypertens Rep. 2012. PMID: 22581395 Review.
Di Luigi L, Romanelli F, Sgrò P, Lenzi A. Di Luigi L, et al. Endocrine. 2012 Oct;42(2):278-84. doi: 10.1007/s12020-012-9655-6. Epub 2012 Mar 20. Endocrine. 2012. PMID: 22430368 Review.
